IGF2BP2 inhibits invasion and migration of clear cell renal cell carcinoma via targeting Netrin‐4 in an m6A‐dependent manner

Abstract

AbstractClear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinoma, often leads to a poor prognosis due to metastasis. The investigation of N6‐methyladenosine (m6A) methylation, a crucial RNA modification, and its role in ccRCC, particularly through the m6A reader insulin‐like growth factor 2 mRNA‐binding protein 2 (IGF2BP2), revealed significant insights. We found that IGF2BP2 was notably downregulated in ccRCC, which correlated with tumor aggressiveness and poor prognosis. Thus, IGFBP2 has emerged as an independent prognostic factor of ccRCC. Moreover, a strong positive correlation was observed between the expression of IGF2BP2 and Netrin‐4. Netrin‐4 was also downregulated in ccRCC, and its lower levels were associated with increased malignancy and poor prognosis. Overexpression of IGF2BP2 and Netrin‐4 suppressed the invasion and migration of ccRCC cells, while Netrin‐4 knockdown reversed these effects in ccRCC cell lines. RNA immunoprecipitation (RIP)‐quantitative polymerase chain reaction validated the robust enrichment of Netrin‐4 mRNA in anti‐IGF2BP2 antibody immunoprecipitates. MeRlP showed significantly increased Netrin4 m6A levels after lGF2BP2 overexpression. Moreover, we found that IGF2BP2 recognized and bound to the m6A site within the coding sequence of Netrin‐4, enhancing its mRNA stability. Collectively, these results showed that IGF2BP2 plays a suppressive role in the invasion and migration of ccRCC cells by targeting Netrin‐4 in an m6A‐dependent manner. These findings underscore the potential of IGF2BP2/Netrin‐4 as a promising prognostic biomarker and therapeutic target in patients with ccRCC metastasis.